Belgian Biotech Ablynx Pushes Aside $3.1B Novo Nordisk Bid
Belgian biotechnology firm Ablynx NV on Monday said it will not accept a $3.1 billion (€2.6 billion) takeover offer by Novo Nordisk AS, saying the deal "fundamentally undervalues" the company and...To view the full article, register now.
Already a subscriber? Click here to view full article